<span item_type="fundamental" item_id="5d82cf4fe496d021cd71a3ea0079c0f6" counter_id="ST/US/ABVC" env="prod"></span><span item_type="announcement" item_id="578680859372558209" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 1.28 M.</p><p></p><h3>Licensing Revenue</h3><ul><li>The company recognized approximately USD 1.28 million in licensing revenue for Q3 2025, compared to USD 0.39 million for the same period in 2024, marking an increase of approximately 230% year-over-year.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1173313/000121390025104900/ea026348101ex99-1_abvcbio.htm"></span></li></ul><h3>Total Assets</h3><ul><li>As of September 30, 2025, total assets were USD 21.18 million, compared with USD 7.54 million at December 31, 2024, representing an increase of approximately 181%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1173313/000121390025104900/ea026348101ex99-1_abvcbio.htm"></span></li></ul><h3>Property and Equipment</h3><ul><li>Property and equipment (net) totaled USD 12.06 million, up from USD 0.51 million at the end of 2024, reflecting a growth of approximately 2,100% due to recent real-asset investments in Taiwan.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1173313/000121390025104900/ea026348101ex99-1_abvcbio.htm"></span></li></ul><h3>Strategic Asset Investments</h3><ul><li>During the third quarter, the company completed two land acquisitions in Taiwan totaling approximately USD 11 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1173313/000121390025104900/ea026348101ex99-1_abvcbio.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>ABVC BioPharma, Inc. continues to develop its dual-core operations between Silicon Valley and Taiwan, focusing on innovation and clinical development, and strengthening Asia-based production and research capabilities. The company maintains multiple licensing agreements that provide potential future milestone and royalty income based on development and commercialization progress. ABVC seeks to advance its key pipeline assets and explore additional partnerships to support its long-term growth strategy.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1173313/000121390025104900/ea026348101ex99-1_abvcbio.htm"></span></li></ul>

ABVC BioPharma | 8-K: FY2025 Q3 Revenue: USD 1.28 M